Last reviewed · How we verify

Letybo® — Competitive Intelligence Brief

Letybo® (Letybo®) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor. Area: Oncology.

marketed FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor FLT3, JAK2 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Letybo® (Letybo®) — Yuvell. Letybo is a tyrosine kinase inhibitor that targets FLT3 and other kinases to inhibit leukemic cell proliferation.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Letybo® TARGET Letybo® Yuvell marketed FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor FLT3, JAK2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (FLT3 inhibitor / multi-targeted tyrosine kinase inhibitor class)

  1. Yuvell · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Letybo® — Competitive Intelligence Brief. https://druglandscape.com/ci/letybo. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: